Utilization of Real-World Data to Facilitate Clinical Trials for Patients with Lymphoma

The future directions in leveraging real-world evidence (RWE) and real-world data (RWD) in the field of lymphoma, as compared to traditional experimental clinical trials, are poised to significantly impact research methodologies, treatment strategies, and patient care. Current methods of clinical tr...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacoepidemiology 2024-08, Vol.3 (3), p.252-264
Main Authors: Chihara, Dai, Hobbs, Brian P., Maurer, Matthew J., Flowers, Christopher R.
Format: Article
Language:English
Subjects:
clinical trial
data science
lymphoma
real-world evidence
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The future directions in leveraging real-world evidence (RWE) and real-world data (RWD) in the field of lymphoma, as compared to traditional experimental clinical trials, are poised to significantly impact research methodologies, treatment strategies, and patient care. Current methods of clinical trials involve a well-controlled design and patient selection bias. Integrating RWE and RWD with experimental clinical trials offers a multifaceted approach to understanding lymphoma and enhancing patient outcomes. In this review, we discuss how RWE has helped shape lymphoma clinical trials, and we compare and evaluate evidence obtained from real-world lymphoma studies/databases with that obtained from clinical trials. We also discuss methods for utilizing surrogate endpoints to facilitate clinical trials and expedite drug development. RWE can be leveraged to bridge the gap between data obtained from clinical trial populations and the broader patient population encountered in clinical practice, by highlighting differences in outcomes and the need for effective treatment strategies across diverse patient groups.
ISSN:2813-0618
2813-0618
DOI:10.3390/pharma3030017